GlassScriptPhysician profile
Richard Fred Weinberger
NPI 1619978517
$4,257.88
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $1,160 · 2021: $441 · 2022: $1,059 · 2023: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $502.01 | 2019-2022 | |
| Lilly USA, LLC | $463.62 | 2019-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $457.49 | 2019-2022 | |
| Abbvie INC. | $375.02 | 2019-2023 | Qulipta |
| Novo Nordisk INC | $370.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $270.80 | 2019-2022 | |
| Amgen INC. | $203.20 | 2019-2022 | |
| Amarin Pharma, INC. | $157.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.95 | 2020-2023 | Ofev |
| Teva Pharmaceuticals USA, INC. | $115.85 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $112.09 | 2019-2020 | |
| Glaxosmithkline, LLC. | $106.89 | 2019-2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $88.74 | 2019-2022 | |
| Astellas Pharma US INC | $86.01 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.45 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $79.57 | 2021-2022 | |
| Allergan, INC. | $70.59 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $66.22 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.02 | 2022 | |
| Merck Sharp & Dohme LLC | $60.41 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $53.89 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.26 | 2021-2023 | Xifaxan |
| Sanofi Pasteur INC. | $44.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.42 | 2019 | |
| Strongbridge US INC. | $23.56 | 2019-2020 | |
| Genzyme Corporation | $23.28 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.10 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.39 | 2022 | |
| Dexcom, INC. | $16.94 | 2022 | |
| Horizon Therapeutics Plc | $16.61 | 2019 | |
| Eisai INC. | $16.14 | 2021 | |
| Shire North American Group INC | $15.77 | 2019 | |
| Medtronic, INC. | $13.59 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Weinberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.